2-(Piperidin-1-YL)ethyl dodecanoate | 191402-39-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-(Piperidin-1-YL)ethyl dodecanoate
• 英文别名: 2-piperidin-1-ylethyl dodecanoate
• CAS: 191402-39-8
• 化学式: C₁₉H₃₇NO₂
• 分子量: 311.5
• InChiKey: FTWDXELUVTYQOT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  22
• 可旋转键数：
  14
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Polymer, resist protective coating material, and patterning process
  申请人：Harada Yuji

  公开号：US20080085466A1

  公开（公告）日：2008-04-10

  A resist protective coating material comprises a polymer comprising repeat units having formulae (1 a ) and (1 b ) and having a Mw of 1,000-500,000. R 1a and R 1b are H, F or alkyl or fluoroalkyl, R 2a , R 2b , R 3a and R 3b are H or alkyl, or R 2a and R 2b , and R 3a and R 3b may bond together to form a ring, 0
• PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS
  申请人：GLYCOREGIMMUNE, INC.

  公开号：US20160158258A1

  公开（公告）日：2016-06-09

  In accordance with some embodiments herein, methods and compositions for prevention and treatment of inflammatory conditions are provided. In some embodiments, compositions comprising NKT-2 activators, for example miltefosine are provided. In some embodiments, the compositions further comprise sulfatide and/or a RAR agonist. In some embodiments, the compositions comprise activators of Type II NKT cells, and/or inhibitors of Type I NKT cells.
• US7670750B2
  申请人：——

  公开号：US7670750B2

  公开（公告）日：2010-03-02
• US7759047B2
  申请人：——

  公开号：US7759047B2

  公开（公告）日：2010-07-20
• [EN] PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS<br/>[FR] PRÉVENTION ET TRAITEMENT DE PATHOLOGIES INFLAMMATOIRES
  申请人：GLYCOREGIMMUNE INC

  公开号：WO2016094226A1

  公开（公告）日：2016-06-16

  In accordance with some embodiments herein, methods and compositions for prevention and treatment of inflammatory conditions are provided. In some embodiments, compositions comprising NKT-2 activators, for example miltefosine are provided. In some embodiments, the compositions further comprise sulfatide and/or a RAR agonist. In some embodiments, the compositions comprise activators of Type II NKT cells, and/or inhibitors of Type I NKT cells.